Abstract: At low doses, ketamine has been found to rapidly improve depressive symptoms. The drug offers a promising alternative to traditional depression treatments such as selective serotonin reuptake inhibitors (SSRIs) and electroconvulsive therapy (ECT), which both require a greater time to achieve therapeutic effect and are overall less effective compared to ketamine. However, ketamine usage raises ethical concerns medical researchers must address: lack of research on long-term effects, accessibility, and potential drug abuse. This essay explores the dual nature of ketamine as both a promising intervention for depression and a source of ethical complexity, and offers suggestions to address these ethical concerns.

​

Background

 

     Ketamine is a dissociative anaesthetic; it distorts perception, making patients feel detached from pain and reality [2]. Additionally, ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist, resulting in NMDA receptor dysfunction. Because abnormal glutamate signaling involving NMDA receptors has been implicated in depression, researchers have investigated whether modulating this pathway with ketamine could alleviate depressive symptoms, particularly in treatment-resistant depression (TRD) [8]. In fact, research has shown that at subanesthetic doses, ketamine displays rapid antidepressant effects [7]. In 2019, the FDA approved esketamine, a ketamine derivative, for prescription nasal sprays [4]. This medical breakthrough can offer fast and effective treatments. However, concerns about insufficient research, harmful symptoms, lack of accessibility, and drug abuse arise in this situation. 

 

Benefits of Ketamine

 

     Ketamine’s rapid antidepressant effects stem from its ability to reverse the neurological damage caused by depression. Chronic stress, a common contributor to depression, reduces the number of dendritic spines on neurons. Thus, impaired neuronal communication hinders cognitive functions and behavioral flexibility [12]. Ketamine promotes the formation of new dendritic spines, helping restore these neural connections. As an NMDA receptor antagonist, ketamine blocks NMDA receptors, resulting in large increases in glutamate levels. This process promotes the release of brain-derived neurotrophic factor, a protein that helps repair synaptic connections [10]. Ultimately, ketamine offers a promising alternative method to reduce depressive symptoms by supporting the development of new dendritic spines and repairing neuronal communication.

     Additionally, ketamine offers faster results and greater efficiency than other interventions to treat depression. Extensive research explores the effects of ketamine on TRD, revealing that it significantly reduces suicidal ideation, self-harm, and general depressive symptoms in short periods of time [11]. In fact, its antidepressant effects can occur within just 40 minutes of administration [4]. Additionally, ketamine displays greater efficacy, quicker results, and more tolerable side effects compared to other antidepressant treatments such as SSRIs, ECT, and tricyclic antidepressants [10]. Ketamine’s proven efficiency is especially critical for patients with TRD, who often endure prolonged treatment cycles with little to no improvement. Overall, ketamine’s rapid effects and efficiency give it promising potential as a transformative intervention for TRD, allowing patients to experience faster results and return to baseline functioning.

​

Ethical Controversies Surrounding Ketamine

 

     While ketamine shows promise in treating TRD, further research must be conducted to address potential safety hazards regarding long-term usage. Although esketamine is FDA-approved, ketamine usage to treat psychiatric disorders is not [3]. A major factor lies in the unknown side effects regarding long-term usage of ketamine. Ketamine may deliver instant improvements, but questions about its long-term stability and maintaining its antidepressant effects are concerns that researchers must address for the safety of patients suffering from TRD. Additionally, compared to the nasally-administered esketamine, ketamine is injected, typically in low doses such as 0.5 milligrams per kilogram. These low doses allow ketamine’s antidepressant effects to prosper while keeping its dissociative symptoms contained. However, ketamine’s effects are only short-term, requiring frequent injections to moderate depression [10]. Therefore, developing ketamine tolerance poses a potential risk in sustained treatment. Larger doses for the same effects involve putting patients at risk of ketamine's adverse side effects, which include intoxication, sedation, hypertension and tachycardia, nausea, and vomiting [4]. For individuals already vulnerable to chronic depression, repeated exposure to a treatment with poorly understood long-term consequences raises ethical red flags. This uncertainty challenges the principle of beneficence, as clinicians must determine whether ketamine's potential benefits outweigh its uncertain long-term risks and whether its use truly serves the patient's best interests. It also complicates the principle of autonomy because incomplete knowledge of long-term outcomes limits clinicians' ability to provide patients with comprehensive information. As a result, making fully informed treatment decisions becomes more difficult for both the clinician and patient. Until more comprehensive research establishes the long-term safety and efficacy of ketamine, its role in treating TRD remains precarious. Such evidence is essential to protect patient safety and ensure that patients can make fully informed decisions about their treatment.

     Beyond concerns regarding long-term safety, ketamine treatment also poses challenges related to the ethical principle of justice, which emphasizes equitable access to healthcare. Although ketamine has shown promise for individuals with TRD, access remains uneven, as insurance coverage for treatment is often limited. This leaves many patients to pay out of pocket, despite intravenous infusions costing thousands of dollars [13]. Consequently, patients receiving ketamine therapy tend to come from higher income brackets, with most belonging to middle and upper-middle classes. Meanwhile, individuals from lower economic backgrounds may face financial barriers to proper medical care [13]. Geographic disparities further compound unequal access, as ketamine clinics and qualified providers are concentrated primarily in urban areas, reducing access for patients living in rural communities [13]. While some providers have attempted to improve accessibility through tiered pricing and installment payment plans, these measures do not fully eliminate the financial and geographic inequities surrounding ketamine treatment [13]. As a result, ketamine treatment for TRD raises ethical concerns about whether all patients have a fair opportunity to benefit from this emerging therapy.

     Ketamine’s known history as a recreational drug poses ethical challenges such as potential drug abuse and misuse. Recreational users often seek ketamine for its dissociative and euphoric effects. Additionally, chronic misuse has been associated with psychological dependence, cognitive impairment, and other health complications [2]. Even in clinical settings, individuals may develop a dependency on ketamine because it provides temporary relief from emotional and physical pain [2]. However, withdrawal symptoms that follow may reinforce repeated use, increasing the risk of psychological dependence. At the biological level, ketamine stimulates mesolimbic regions, such as the amygdala and insula, to nullify negative stimuli. Consequently, patients may become incentivized to reuse ketamine to gain relief from aversive psychological states [10]. This potential for dependence raises significant concerns regarding patient safety and the risk of drug abuse. As a result, the dichotomy of ketamine’s effects presents an ethical paradox: ketamine can help treat depression, but its dissociative and negative symptoms introduce new psychological problems. Furthermore, a lack of medical supervision during ketamine administration puts patients at risk for similar problems. For example, in 2023, a patient experienced respiratory depression after taking ketamine outside of a professional healthcare setting [3]. This case exemplifies the dangers of unsupervised ketamine use and underscores the need for strict medical oversight to prevent serious health complications. Given ketamine’s potential for misuse, its widespread adoption as a treatment for TRD raises questions about whether ketamine aligns with the ethical and medical principle of non-maleficence, which encourages medical professionals to prioritize minimizing harm to patients.

 

Conclusion and Future Suggestions

 

     Ketamine shows promise as an effective treatment for TRD. However, the challenges that accompany it should first be addressed before legitimising this intervention. First, more extensive research on ketamine’s long-term antidepressant and dissociative properties must verify its stability and effectiveness. This would provide a better understanding of potential health benefits and issues that ethical questions require answers to. Additionally, stricter policies regarding ketamine dosage and supervision are essential to prevent serious health hazards and drug abuse. Once these two conditions are established, it is imperative to expand access to ketamine treatment, as economic and geographical barriers shouldn’t prevent individuals with TRD from receiving proper care. While ketamine is not a perfect solution, it remains a hopeful option for individuals seeking relief from the burdens of chronic TRD. With continued research and appropriate medical oversight, ketamine has the potential to become a valuable treatment for TRD while upholding the ethical responsibility to prioritize patient safety.